Drugs / Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine，Recombinant (Hansenula polymorpha)

Follow last change Jul 2025 re-read 3 minutes ago

Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine，Recombinant (Hansenula polymorpha)

Developed for: norovirus infectious disease
Investigated by: Lanzhou Institute of Biological Products Co., Ltd · National Vaccine and Serum Institute, China

today NCT05916326 · Ph 3

202420252026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 3	NCT05916326	Jun 2023 → Jul 2025	norovirus infectious disease	National Vaccine and Serum Institute, China	Completed	No outcome recorded

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine，Recombinant (Hansenula polymorpha)	ClinicalTrials.gov intervention name — accepted as the source's own label NCT05916326 ↗
Modality	Vaccine	“Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine，Recombinant (Hansenula polymorpha)” NCT05916326 ↗
Route	Intramuscular	“Intramuscular injection of Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine，Recombinant (Hansenula polymorpha) in the deltoid muscle of the upper arm” NCT05916326 ↗